Longeveron Inc. (LGVN)
NASDAQ: LGVN · Real-Time Price · USD
0.868
-0.016 (-1.82%)
Apr 29, 2026, 1:21 PM EDT - Market open
Company Description
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States.
Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 3 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer’s disease, as well as in phase 2b clinical trial to treat aging frailty.
The company was incorporated in 2014 and is headquartered in Miami, Florida.
Longeveron Inc.
| Country | United States |
| Founded | 2014 |
| IPO Date | Feb 12, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 38 |
| CEO | Stephen Willard |
Contact Details
Address: Life Science & Technology Park, Suite 520 Miami, Florida 33136 United States | |
| Phone | 844 470 2550 |
| Website | longeveron.com |
Stock Details
| Ticker Symbol | LGVN |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Share Class | Class A Shares |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $10.00 |
| CIK Code | 0001721484 |
| CUSIP Number | 54303L104 |
| ISIN Number | US54303L2034 |
| Employer ID | 47-2174146 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Stephen H. Willard Esq. | Chief Executive Officer |
| Dr. Joshua Michael Hare FACC, M.D. | Co-Founder, Chief Science Officer and Executive Chairman |
| Lisa A. Locklear M.B.A. | Chief Financial Officer, Executive Vice President and Treasurer |
| Paul T. Lehr J.D. | General Counsel and Secretary |
| Devin Blass | Chief Technology Officer and Senior Vice President of Chemistry, Manufacturing and Controls |
| Dr. Nataliya Agafonova M.D. | Chief Medical Officer |
| Lisa McClain-Moss | Vice President of Manufacturing |
| Brian G Rash Ph.D. | Vice President of Research and Discovery |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 17, 2026 | EFFECT | Notice of Effectiveness |
| Apr 17, 2026 | 424B3 | Prospectus |
| Apr 10, 2026 | 8-K | Current Report |
| Apr 10, 2026 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Mar 25, 2026 | 8-K | Current Report |
| Mar 25, 2026 | D | Notice of Exempt Offering of Securities |
| Mar 24, 2026 | 8-K | Current Report |
| Mar 17, 2026 | 10-K | Annual Report |
| Mar 12, 2026 | 8-K | Current Report |
| Mar 9, 2026 | 8-K | Current Report |